|
Sinoway Industrial Co.Ltd.
|
Product name
|
Imatinib Mesylate
|
Molecular Formula
|
C30H35N7O4S
|
Molecular Weight
|
589.71
|
CAS No.
|
220127-57-1
|
Quality Standard
|
In-house standard
|
Appearance
|
White powder
|
TEST ITEMS
|
SPECIFICATION
|
RESULTS
|
Appearance
|
White or slightly yellow crystalline powder,
homogeneous and with fine grain size.
No foreign particles are observed.
|
Slightly yellow crystalline Powder
|
Solubility
|
Soluble in water and in acids solutions, slightly soluble
in methanol insoluble in acetone, acetonitrile and
dilute hydroxyl alkaline solution
|
Confirm
|
Identification
|
Complies
|
Confirm
|
Water
|
≤1.0%
|
0.8%
|
Heavy metals
|
≤20ppm
|
10ppm
|
Melting range
|
212 – 220℃
|
214-216℃
|
Residue on ignition
|
≤0.1%
|
0.08%
|
Particle size
|
90% < 100 μm
50% < 50 μm
|
Confirm
|
Bulk density
|
NLT 0.4g/ml
|
0.6g/ml
|
Chromatographic
purity
|
Individual impurities: ≤0.2%
Total impurities: ≤0.5%
|
0.16%
0.32%
|
Assay
|
98.5%-102.0% of Imatinib mesylate,
calculated on anhydrous basis.
|
99.70%
|
Residual solvents
|
Ethyl acetate: ≤5000ppm
|
Confirm
|
Acetone: ≤5000ppm
|
Confirm
|
N,N-Dimethylformamide: ≤880ppm
|
Confirm
|
Methanol: ≤3000ppm
|
Confirm
|
Dichloromethane: ≤300ppm
|
Confirm
|
We provide you with high-quality imatinib mesylate powder and imatinib mesylate price is very reasonable and competitive.
Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl,
the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of
dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.
1. A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
2. Echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
3. Anticancer |
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
